Click Here to return To Results

 

Intramuscular Interferon Beta-1a Therapy Initiated During a First Demyelinating Event in Multiple Sclerosis NEJM 343:898-904, Jacobs,L.D. et al, 2000 See this aricle in Pubmed Article Abstract During three years of follow-up, the cumulative probability of the development of clinically definite multiple sclerosis was significantly lower in the interferon beta-1a group than in the placebo group (rate ratio, 0.56; 95 percent confidence interval, 0.38 to 0.81; P=0.002). As compared with the patients in the placebo group, patients in the interferon beta-1a group had a relative reduction in the volume of brain lesions (P<0.001), fewer new or enlarging lesions (P<0.001), and fewer gadolinium-enhancing lesions (P<0.001) at 18 months. Initiating treatment with interferon beta-1a at the time of a first demyelinating event is beneficial for patients with brain lesions on MRI that indicate a high risk of clinically definite multiple sclerosis.

Related Tags

(click to filter results - removes previous filter) interferon interferon beta 1-a MRI,abnormal multiple sclerosis multiple sclerosis,monosymptomatic multiple sclerosis,treatment of multiple sclerosis,treatment of,first attack treatment of neurologic disorder

Click Here to return To Results